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Withdrawal of antihypertensive therapy in
people with dementia: feasibility study
Veronika van der Wardt1* , Jennifer K. Burton2, Simon Conroy3, Tomas Welsh4, Pip Logan1, Jaspal Taggar5,
Lukasz Tanajewski6,7 and John Gladman1
Abstract
Background: This study explored the feasibility of a randomised controlled withdrawal trial of antihypertensive
medication in normotensive people with dementia. Feasibility aspects included response, recruitment, exclusion
and drop-out rates, suitability of outcome measures, acceptability of study procedures and an indicative economic
evaluation for a randomised controlled trial.
Methods: A cohort study attempting the withdrawal of antihypertensive drugs where appropriate and a feasibility
study of home-based blood pressure monitoring, in people with dementia treated for hypertension, was undertaken.
Interviews with participants and carers and an indicative economic evaluation were also undertaken.
Results: Three hundred and sixty-two primary care practices in the East Midlands were contacted of which only 41
(11% (95%CI 8–15%)) agreed to support the study. These 41 practices posted 940 letters to potential participants.
Thirty participants were enrolled in the cohort study of whom 9 were eligible for the antihypertensive withdrawal
programme, 20 participated in a home blood pressure monitoring sub-group analysis and 12 took part in an
interview study. Twenty-two of those enrolled in the cohort study were followed up at 6 months. The withdrawal
programme was acceptable to participants and general practitioners (GPs). The study procedures including
assessments and home blood pressure monitoring were acceptable to the participants and their carers. The
economic evaluation was not possible.
Conclusion: A withdrawal trial of antihypertensive medication in normotensive people with dementia may not be
feasible in the UK because of low recruitment rates.
Keywords: Hypertension, Dementia, Antihypertensive medication, Withdrawal, Cessation, Feasibility study, Patient
experience, Recruitment, Primary care
Background
People with dementia are at greater risk of the adverse
effects of antihypertensive medications, such as falls and
syncope, than those without dementia due to their in-
creased frailty and autonomic instability [1]. Antihyper-
tensive medication can contribute to polypharmacy,
which is particularly common and troublesome in
people with dementia partly due to the cumulative bur-
den of anticholinergic activity [2]. These increased con-
cerns about the use of antihypertensive therapy in
people with dementia are of particular importance
because the balance of benefits and harms from antihy-
pertensive therapy is unclear in this population [3].
Given that it is reported that antihypertensive medica-
tion can be discontinued for 1 year or more without
hypertension returning in 44–66% of people with well-
controlled hypertension [4–6], a large randomised
controlled trial (RCT) of antihypertensive withdrawal to
examine the balance of benefits and harms in this popu-
lation may be justified.
We aimed to conduct a study to investigate the feasi-
bility of undertaking a larger randomised trial of the
withdrawal of antihypertensive medication in patients
with dementia. The research questions of this study were
as follows:* Correspondence: v.vanderwardt@nottingham.ac.uk1Division of Rehabilitation and Ageing, School of Medicine, University of
Nottingham, Nottingham NG7 2UH, UK
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1. Can suitable and adequate numbers of potential
participants for a RCT be identified?
2. Will suitable and adequate numbers of potential
participants give consent to a RCT?
3. Are the trial procedures for a RCT including
communication, consent procedure, documentation
and assessments acceptable to participants?
4. Are the proposed trial baseline and outcomes
measures suitable (i.e. minimal missing data)?
5. Can the intervention to withdraw antihypertensive
medication be put into practice adequately for
testing in a RCT and in anticipation of subsequent
wider adoption?
6. What is the evidence in the scientific literature from
a health economics perspective that supports or
limits the justifiability of a RCT?
Methods
Research ethics
The study was approved by the West Midlands Health
Research Ethics Committee [reference: 13/WM/0468].
Participants provided written informed consent or con-
sultees provided written informed agreement.
Methodology
To answer these six research questions, our study com-
prised the following elements: a cohort study comprising
medication withdrawal, home blood pressure monitoring
and an interview sub-study was undertaken. The medi-
cation withdrawal sub-study included plans for an indi-
cative economic evaluation.
The cohort study was conducted using identification
and recruitment processes from primary care databases
that would be used in a subsequent RCT. We aimed to
study all the potential participants identified from gen-
eral practitioner (GP) databases who would meet the se-
lection criteria for a subsequent RCT. Identification of
potential participants via memory clinics was explored
but not pursued because the local memory clinics were
at research capacity and would not necessarily engage
GPs who would be essential to oversee the eventual
withdrawal of antihypertensive medication. Identification
of potential participants via a national website specific-
ally to support the engagement of patients in research
(Join Dementia Research website [7]) was explored but
led only to one potential participant who expressed
interest but who did not consent to participate.
As we suspected that recruitment via GP databases
was likely to identify some people who were ineligible
for withdrawal due to inadequate recording in those da-
tabases of the selection criteria, we undertook a further
assessment of those enrolled in the cohort study to as-
sess their true eligibility for withdrawal of their antihy-
pertensive medications, whilst evaluating the feasibility
of the follow-up RCT trial procedures in the overall
cohort to answer research questions one, two and four.
An antihypertensive therapy withdrawal procedure, de-
veloped for this study, was applied to those who met the
selection criteria after further clinical assessment (the
withdrawal sub-study) to answer research question five.
The feasibility of home-based blood pressure monitor-
ing (HBPM) in a sub-group of cohort study participants
was tested to contribute to research question five, as
HBPM is part of best clinical practice [8] and was
suggested to be incorporated in hypertension trials [9],
and we anticipated that it could ensure greater safety
during antihypertensive therapy withdrawal than weekly
or monthly clinic measurements.
We undertook an interview study with a sub-group of
the participants to answer research question three and
explore cohort study participants’ views and experience
of research participation.
We attempted to conduct an indicative economic
evaluation of the withdrawal procedure, combining the
results of a literature analysis and the results of the
cohort study in a Markov model, to answer research
question six.
Cohort study: identification of potential participants
Potential participants were identified through GP prac-
tices in Nottinghamshire, Leicestershire and Derbyshire
(East Midlands, UK). GP practices, contacted by phone
and/or email, were provided with study information and
asked to assist in the recruitment process. Practices that
did so were reimbursed £70 independent of subsequent
recruitment. Practices were approached via the Clinical
Research Network (CRN) and via the research team
directly when the CRN did not have contacts to the
practice. Practice responses and reasons for not assisting
the recruitment process were recorded.
General practices that agreed to assist in the identifica-
tion of potential participants were requested to screen
their practice lists and databases for the following:
 Those with a diagnosis of dementia and a diagnosis
of hypertension who were receiving antihypertensive
treatment
 Who were aged 18 years or older
 Had no transient ischemic attack, stroke or myocardial
infarction in the last 12 months
 Had no previous malignant hypertension, left
ventricular failure or congestive cardiac failure
 Were not under-treated for hypertension (sitting
blood pressure (BP), re-assessed by the research
nurse at baseline by measuring the participant’s BP):
systolic BP ≥ 150 mmHg or diastolic BP ≥ 90 mmHg
on two separate occasion in people 80 years or over,
or BP > 140/80 mmHg in people under 80 years of
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age, or BP > 130/80 mmHg in people with diabetes
and chronic kidney disease (any state) or BP > 130/
80 mmHg in people with chronic kidney disease
(any stage) and proteinuria (ACR ≥ 70)
People identified from the screening of GP databases
who met the above criteria were contacted by their prac-
tice by post, given information about the study and
invited to contact the research team by post, email or
telephone if they were interested in participating.
Cohort study: recruitment of participants
Potential participants who expressed interest in the
study were contacted by telephone to discuss the study
and ensure that they were living with a carer. If inter-
ested in participating in the study, the research team
sent further study information by post and arranged the
baseline visit. The participant information sheet ex-
plained the purpose of the study, the potential frequency
and duration of visits, and the procedures as well as
potential risks and benefits of taking part. Carers were
invited to participate in the interview study separately.
Signed participant consent or consultee agreement was
completed prior to the baseline assessment either from
the participant with the mental capacity to do so
(consent) or from the carer in cases where the partici-
pant did not have mental capacity (agreement). Partici-
pation in home blood pressure monitoring (HBPM) was
optional and included in the consent/agreement form.
Baseline and follow-up assessments
Follow-up took place 6 months after the baseline assess-
ment irrespective of the lengths of withdrawal proced-
ure. All recruited participants (apart from those who
were excluded when found not to be on antihypertensive
medication) were invited to complete follow-up assess-
ments. Participants’ demographic characteristics were
assessed at baseline only, and the National Health
Service (NHS) use and potential side effects associated
with antihypertensive therapy were recorded at both as-
sessments. Based on a systematic scoping review of do-
mains potentially affected by antihypertensive therapy
[3], scales for cognition, depression, agitation, sleep
quality and functional ability were selected. A quality of
life scale was added to support the health economics
evaluation.
The following assessment scales were used at baseline
and follow-up assessment:
 Global cognition (Montreal Cognitive Assessment
(MoCA); [10])
 Depression (Cornell scale; [11])
 Agitation (CMAI; [12])
 Sleep disturbances (NPI-SD; [13])
 Functional ability (Disability Assessment for
Dementia (DAD); [14])
 Activities of daily living (Barthel index; [15])
 Quality of life (DEMQOL; [16])
Wherever possible, outcomes were ascertained directly
from participants, but where cognition precluded out-
come completion, proxy questionnaire versions were
used. Answers reflecting the situation most accurately in
the view of the research nurse were used to complete
the questionnaires.
At baseline and follow-up assessments, blood pressure
(BP) was measured twice on each arm after sitting for
5 min and standing. BP was measured on the arm with
the lower sitting BP after lying down for 3 min and
standing up for 1 min. Symptoms of orthostatic
hypotension were recorded. A blood sample was taken
at baseline to assess kidney function.
Withdrawal programme
A research nurse confirmed that the inclusion and ex-
clusion criteria used in the identification process were
valid, applied a final section process to exclude those
with over-treated and uncontrolled hypertension and
collected the medical history and prescription data ne-
cessary to make the decision to attempt antihypertensive
withdrawal.
A senior geriatrician from the research team used the
results of these assessments and a summary of the par-
ticipant’s medical history obtained from the GP to deter-
mine whether they were suitable for withdrawal of their
antihypertensive medications and, if they were, drew up
an individualised antihypertensive withdrawal plan. The
antihypertensive withdrawal plan was developed by the
study team [17] based upon guidance from previous
studies, national prescribing guidance and NICE guide-
lines for the use of antihypertensive therapy. A key
principle of the withdrawal plan was that BP medication
should be withdrawn gradually with the duration of the
process depending on the number and type of medica-
tion taken [8]. During the withdrawal procedure, each
week, the nurse monitored the participants’ blood
pressures, adverse events, symptoms related to antihy-
pertensive medication use, change in medication and
visits to or from health professionals. If antihyperten-
sives were withdrawn, monitoring visits took place
monthly. After every visit, the participant’s GP was
informed of the results.
Participants’ GPs were informed of the withdrawal
plans and were asked to agree to them. The research
nurse undertook the implementation of the plan by tak-
ing and recording blood pressure measurements and
informing the GP of what dose adjustments to antihy-
pertensive therapy were required in line with the
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individualised plan. The ultimate decision to implement
the withdrawal programme or to re-start antihyperten-
sive therapy remained with the GP: the withdrawal
procedure plans were advisory.
Home blood pressure monitoring study
At recruitment to the cohort study, participants were
asked if they would like to take part in a 1-week home
blood pressure monitoring sub-study. Each participant
who agreed to participate in the home blood pressure
monitoring sub-study received a British Hypertension
Society-approved Kinetik monitor with the appropriate
cuff, a large letter version of its instruction booklet and
a record sheet to note down all measurements. Follow-
ing instructions on how to use the blood pressure moni-
tor, the research nurse completed the first measurement
and recorded the results. Following NICE guidelines for
hypertension [8], participants were asked to complete
the measurements for the rest of the week in the morn-
ing and in the evening, each time on both arms, either
on their own or with the help of their relative.
Interview study
Participants and their spouses in the cohort study were
also invited to take part in an interview sub-study.
Consent for interviews was sought from participants and
carers separately. Recruitment to the interview study oc-
curred until the analysis of the transcripts indicated that
no new themes emerged. Semi-structured interviews
were conducted by a research team member (VvdW) at
each participant’s home. An interview schedule guided
the interviews and outlined questions regarding the deci-
sion to take part and consent to the study, thoughts and
feelings around stopping antihypertensive therapy and
about the study procedures including home blood pres-
sure monitoring. Participants and family members could
choose if they wanted to complete the interviews separ-
ately or together.
Indicative economic evaluation
A Markov model was planned to estimate the long-term
health and economic effects of the withdrawal of antihy-
pertensive therapy in people with dementia. The param-
eters required for such a model included the costs and
outcomes (vascular event, progression of dementia, falls,
etc) of usual care and care when withdrawal was under-
taken and the likelihood of successful withdrawal. These
parameters were to be drawn from previously published
literature and the findings of the cohort study.
Analyses
Descriptive statistics of the findings of the identification
and recruitment processes were used to answer research
questions 1 and 2 (identification and recruitment).
Research question 3 (acceptability) was answered from
the interview study using qualitative analysis. Audio re-
cordings of the interviews were transcribed by a profes-
sional transcriber into a word document, and data were
imported into QSR Nvivo 11 software. The interviewer
(VvdW) analysed the text for emerging themes, which
served as guiding framework for coding and analysis.
The analysis was a continuing process throughout the
interview study. Quotes representing the themes were
identified and compared with the transcript to be used
in the appropriate context.
Research question 4 (suitability of measures) was
answered by examining the completion rates at baseline.
Mean systolic and diastolic BP levels for sitting measure-
ments were calculated and described. Data for NHS
service use, potential side effects of antihypertensive
treatment (AHT) and kidney function were collected to
explore practicability and acceptability of data collection
but are not reported in the “Results” section. All quanti-
tative analyses were completed in Stata version 13.
Research question 5 (practicality of intervention) was
examined based on number of people eligible for the
withdrawal procedure, descriptive statistics of these par-
ticipants, time until hypertension returned and adverse
events. The suitability of home-based blood pressure
monitoring was investigated based on the number of
participants completing this sub-study and the propor-
tion of participants missing six or more measurements
out of a total of 28 over 1 week.
There were no pre-planned analyses for research
question 6.
Results
Identification and recruitment
Recruitment was completed between June 2014 and June
2015. Forty-one of 362 (11%) primary care practices in
the East Midlands who were contacted agreed to
support the study and screened their databases. Those
who decided not to support the study and provided rea-
sons (n = 112) indicated the following reasons:
 Too busy (n = 58, 52%)
 Undergoing practice or staff changes or were short
staffed (n = 20, 17%)
 Not receiving sufficient funding for supporting the
study (n = 10, 9%)
 Already supporting studies and at research capacity
(n = 9, 8%)
 Not an appropriate practice for the study due to
their patient list (n = 9, 8%)
 Not supporting research in general (n = 4, 4%)
 Not interested in supporting this particular study
(n = 2, 2%)
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The 41 supporting practices sent out a total of 940 let-
ters (mean 23 per practice) from which a total of 68 re-
plies (mean 1.7 per practice) were received from
interested participants. Following the pre-interview tele-
phone conversation, 30 out of 68 remained interested and
met the eligibility criteria and agreed to an appointment
for a baseline assessment. The remaining 38 did not want
to participate (n = 22) or were not eligible (n = 16).
We recruited 30 participants diagnosed with dementia
and hypertension (mean age 70.2 years (SD 6.9); range
56–93 years; women n = 13; mean years of education 12
(SD 4.3); ethnicity 93% white) and assessed 22 partici-
pants at follow-up. Losses occurred due to withdrawing
consent or not meeting eligibility criteria (not using
AHT). Three participants withdrew their consent, and
one participant died after the baseline assessment. Four
participants were not using AHT at the point of the
baseline assessment. Figure 1 shows the participant flow.
Withdrawal sub-group analysis
Nine participants (mean age 80.1 years (SD 5.2); five
women; mean number of antihypertensive agents 1.6)
were suitable for the withdrawal procedure. The mean
baseline systolic BP of this group was 131 mmHg (SD
6.8), and the mean baseline diastolic BP was 72 mmHg
(SD 10.6). There was no significant difference in the
numbers of antihypertensive agents taken between those
eligible for withdrawal and those not eligible.
None of the nine participants who completed the
withdrawal procedure were both off antihypertensive
therapy and normotensive at 6 months. Three partici-
pants whose blood pressures had reached the threshold
Fig. 1 Participant flow
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for re-starting antihypertensive therapy were not taking
them at follow-up, following the decision of their treat-
ing GP not to re-start them. The time between starting
withdrawal and when blood pressure limits were
exceeded ranged from 1 to 9 weeks (mean 2.4 weeks; SD
2.8). No adverse events related to the withdrawal
procedure occurred.
Home blood pressure sub-group analysis
In total, 20 participants completed the home blood pres-
sure monitoring study. Four participants (20%) missed
six or more measurements out of the total 28 measure-
ments over the week.
Home blood pressure monitoring was new to the ma-
jority of participants but once they understood the
instructions, they seemed to cope with it very well.
One participant had minor difficulties completing the
record sheet.
One participant and their relative used their own BP
monitor, an Omron M3 device. Two participants experi-
enced pain when using the home blood pressure moni-
tor and withdrew from this part of the study.
Acceptability of trial procedures
The quotes to support the following themes are pre-
sented in Table 1.
Participation and consent (themes 1 and 2)
Several sub-themes for reasons to support the study and
thoughts around consent emerged in the interviews: al-
truism, the possibility to reduce medication and personal
learning. The expression of altruistic reasons was com-
mon with respondents acknowledging that the results of
the feasibility study might not help themselves but might
help others or research in general. One person also
expressed the wish to give something back in return for
the help that they had received.
Another sub-theme (theme 3) was the possibility
that participation might reduce the number of drugs
the participant had to take. This was perceived as a
potentially positive consequence of the study. One
participant also expressed a worry about taking tab-
lets that might not be needed. Furthermore, personal
learning (theme 4) and interest in the topic were
mentioned as reasons to support the study. Some
Table 1 Supporting quotes for acceptability of trial procedures
Participant/
relative
Theme/sub-theme Quote
Relative C 1—Participation and consent/ altruistic reasons ‘I’m all for any research … won’t benefit me but it’ll probably benefit somebody
else.’
Participant D 2—Participation and consent/ altruistic reasons ‘I feel that I need help from you, so I want to give something back.’
Relative E 3—Participation and consent/ participation might
reduce number of drugs
‘…anything to do with reducing the tablets is good.’
Participant F 3—Participation and consent/ participation might
reduce number of drugs
‘I was hoping that they could reduce it [the medication].’
Participant B 3—Participation and consent/ participation might
reduce number of drugs
‘…if you can go without any tablets, it surely has got to be better for you.’
Relative A 4—Participation and consent/ personal learning ‘…perhaps I’m learning things that I don’t know anything about.’
Relative E 5—Participation and consent/ worries but also hope ‘I was a bit dubious because I didn’t know which way it was going to go,… But
when [the GP] confirmed it, he thought it’d be good, and I can, I was all right
then.’
Relative G 5—Participation and consent/ worries but also hope ‘…if it can help him to be, you know, all right longer, it’s worth it’.
Relative H 6—Reflections of assessments and other study
procedures /feeling comfortable
‘They [the questions] were alright…didn’t worry me at all.’
Participant I 6—Reflections of assessments and other study
procedures/high number of questions
: ‘…a lot of them, a lot of questions…’
Relative J 6—Reflections of assessments and other study
procedures/high number of questions
‘No, it’s fine, I mean, don’t mind us answering questions at all, you know, it
don’t, you know, if it helps, it doesn’t matter, does it really. ’
Relative H 6—Reflections of assessments and other study
procedures/high number of questions
‘No problem at all.’
Relative G 6—Reflections of assessments and other study
procedures/ positive to have someone coming
‘It’s nice to know somebody’s there, that’s what…isn’t it?…somebody coming.. .’
Relative H 6—Reflections of assessments and other study
procedures/ positive to have someone coming
‘I loved them coming’.
Relative K 6—Reflections of assessments and other study
procedures/ memory questions
‘…some of the questions were referenced towards the memory problems…
and [name of spouse] got a bit stressed out.’
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carers also expressed worries but also hope when dis-
cussion the initial thoughts about the study and their
thoughts and feelings regarding consenting to the
study (theme 5).
Assessments and other study procedures (theme 6)
In general, participants felt comfortable with the assess-
ments. Some participants noticed that the baseline and
follow-up assessments included a large number of ques-
tions, but did not comment negatively upon that. Some
relatives also indicated that it was positive to have some-
one coming to their home. One participant did not like
all the questions and the spouse indicated that the mem-
ory questions in particular made the participant
uncomfortable.
Suitability of measures
At baseline, 27 out of 30 participants (90%) com-
pleted all measurements. One participant completed
all measures except the CMAI and two participants
did not complete the questionnaires (one due to
withdrawing consent, one completed only the demo-
graphic and health questionnaires). At follow-up, 20
out of 22 participants (91%) completed all measure-
ments. For two participants, BP monitoring was too
painful and two participants did not complete the
MoCA.
Mean BP levels and scores of the questionnaires at
baseline are shown in Table 2 in order to describe the
cohort sample. The average duration of the baseline as-
sessments was 153 min.
Indicative economic evaluation
Because of the low number of participants, no useable
data from the cohort study were obtained for eco-
nomic evaluation parameters. Regarding the Markov
model, the team determined that there was conflicting
evidence about whether it is not known if antihyper-
tensive therapies could have protective or harmful ef-
fects regarding cognition [18–21] and other events
such as falls [1, 22, 23] and on how to design the de-
tailed model structure; the data for such a model
were not available from the literature. It was con-
cluded that it was not possible to develop a Markov
model on existing evidence.
Discussion
Despite inviting 362 primary care practices in the East
Midlands (approximate population 2.5 million) and
sending 940 letters to potential participants, only nine
participants were recruited for the withdrawal proced-
ure. The trial procedures and assessments, including
home blood pressure monitoring, were generally feasible
and acceptable to participants. There was insufficient
information to develop a useful economic model of the
potential effects of withdrawing antihypertensive therapy.
There were two reasons for the low recruitment rate:
the low rate of engagement of general practices willing
to support the study (11%) and the low rate of recruit-
ment of those who were identified (< 1% were suitable
for withdrawal). The involvement of general practi-
tioners GPs and hence recruitment via general practices
was considered to be essential for the withdrawal study
as GPs have responsibility for the management of anti-
hypertensive therapy. The low engagement rate of gen-
eral practices was seen despite the support from the
Clinical Research Network, which is intended to support
the conduct of research in the UK’s health service, and is
likely to reflect the pressure which UK primary care
practices experienced during the study period. Only a
small number of practices indicated they did not want to
support this study in particular (2%), but an additional
10% indicated that they would not receive enough com-
pensation funds for this study. However, the feedback
suggested that the lack of time and staff could affect re-
search in GP practices in general. We have no reason to
think that the engagement of general practices would be
better in any other part of the UK although specific
characteristics of the GP practices involved in the study
were not investigated. A randomised controlled with-
drawal trial conducted in a similar period in the
Netherlands successfully recruited 385 participants from
primary care practices within 26 months (DANTE [24]),
although it had less stringent entry criteria than we ap-
plied. Thus, higher levels of general practice engagement
and hence potential recruitment of participants might be
possible in other countries or in the UK if conditions
changed in the future. However, as < 1% of those con-
tacted by their GPs in the current study were enrolled in
the withdrawal programme, this low recruitment rate
would still limit the feasibility of a RCT using these
Table 2 Baseline measurements
Baseline
N
Mean systolic BP in mmHg (SD) 28* 141.5 (20.5)
Mean diastolic BP in mmHg (SD) 28* 74.9 (13.9)
MoCA mean score (SD) 28* 14.8 (6.3)
Barthel index mean (SD) 28* 82.5 (24.4)
DAD mean score (SD) 28* 57.8 (31.5)
Cornell mean score (SD) 28* 6.6 (5.8)
DemQoL mean score (SD) 28* 88.2 (16.3)
CMAI mean score (SD) 27*+ 17.6 (5.9)
NPI-SD mean score (SD) 28* 1 (1.9)
*One participant only completed demographic and health questionnaires;
+One participant did not complete CMAI
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methods. Even taking all participants who consented
into account, the recruitment rate in this study (3.2%) is
considerably lower than the 11% of people with demen-
tia that have been suggested would take part in drug tri-
als [25]. A narrative review of barriers to prescribing and
deprescribing in people with dementia identified fear of
negative consequences of stopping medication, inability
to change medication taking habits and established be-
liefs in benefits and harms of medication use [26]. These
factors might have played a role in our study. Future
studies may need a more personalised approach to en-
courage patients and their carers to participate, and this
would require considerably more resources than the
postal/telephone process used in this study.
The proposed RCT intervention—withdrawal of anti-
hypertensive drugs—was acceptable to GPs, patients and
their carers. The trial procedures were also acceptable,
including the use of home blood pressure monitoring.
Thus, if higher rates of general practice engagement and
recruitment of participants were to be possible, then a
trial of withdrawal of antihypertensive medications using
these methods would be feasible. However, although this
feasibility study was not designed and powered to esti-
mate the proportion of participants who could withdraw
antihypertensive and remain normotensive for a sus-
tained period, the fact that none of the nine in whom
withdrawal was attempted did so raises concerns that
the methods we used selected a group of patients who
would be unlikely to benefit and hence that a RCT using
these methods would be unwarranted. The methods we
used took into account the need in this vulnerable group
of people to ensure their safety and was conducted in
the context that guidelines for the treatment of hyper-
tension [8] imply that those with dementia should be
treated similarly to those without dementia and where
these guidelines do not advise routinely attempting the
withdrawal of antihypertensive drugs in patients who are
normotensive. We also excluded those with end organ
damage or recent vascular events that might put them at
particular risk from recurrent hypertension. The with-
drawal plan [17] was based on previous studies and
hypertension guidelines for people without dementia as
there was insufficient evidence to conclude that with-
drawal should be different for people with dementia
[27]. Furthermore, modern management of hypertension
in primary care in the UK is incentivised to optimise BP
control. For all these reasons, we are likely to have se-
lected a group of stable patients with a low probability
of being able to withdraw antihypertensive drugs
successfully. Further studies of withdrawal of antihyper-
tensive drugs in people with dementia might be more
worthwhile if focussed upon those at particular risk such
as those with severe dementia, in care homes, with low
BPs on more than one antihypertensive agent.
Conclusion
Given the potential difficulties highlighted in this study
in the conduct of a RCT in this group of patients, an al-
ternative approach to investigate the benefits and harms
of antihypertensive drugs in people with dementia might
be to examine large primary care datasets to ascertain
the benefits and harms of antihypertensive treatment in
people with dementia.
In summary, the low recruitment rates found in this
feasibility imply that a large RCT using a similar method
in the UK would not be feasible.
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